focus -WSS

focus

author：explore 2025-09-03 07:55:12 - browse：25255

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Changes to biosimilar regulatory framework must prioritize patients

focus

WSS

CDC's new outbreak response network to include Northeastern

Patient advocates sound warning on FDA proposal on salt intake

What Congress can do to address the rural doctor shortage

Evacuations in place as 3 wildfires burn in eastern Washington state

Clinical trials must include more disabled people

The boys, now 6, who are gene therapy’s ‘edge case’ problem

hotspot

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Lasker Awards 2023: Winners in biomedical research

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech lab space demand falls sharply

Medical leaders decry Supreme Court decision on affirmative action

New definition of a human embryo proposed amid rapid advances

In age of alternative facts, a scholarly course on calling out crap

Living with Hashimoto's and celiac disease, and med school, too

As demand for Covid shots wanes, Moderna seeks its next success

CDC's new outbreak response network to include Northeastern

hotspot

Lasker Awards 2023: Winners in biomedical research

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

CDC advisers recommend seasonal use of Pfizer RSV shot

ProMED sees offers of support, but its future remains unclear

FDA approves first treatment for ultra

An interview with Robert F. Kennedy Jr. on vaccines

focus

focus

knowledge

explore